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ABSTRACT
Introduction: Prevention of relapse is a major
challenge in schizophrenia, a disease charac-
terized by poor adherence to antipsychotic
medication leading to multiple rehospitaliza-
tions and a substantial burden-of-care.
Methods: We narratively review published
clinical data from the development of
long-acting injectable (LAI) formulations of
antipsychotic drugs and examine the compara-
tive effectiveness of oral versus LAIs in
schizophrenia, with a focus on the sec-
ond-generation LAI antipsychotic aripiprazole.
Evidence is presented from studies with
naturalistic/pragmatic as well as explanatory
trial designs, supported by the clinical experi-
ence of the authors.
Results: LAI formulations of antipsychotic
drugs offer advantages over oral medications
and there is good evidence for their use as a
first-choice treatment and in younger patients.
Key phase III studies have shown aripiprazole
once-monthly 400 mg (AOM 400) to be effec-
tive and well tolerated, with high rates of
adherence and low rates of impending relapse.
In a recent randomized trial with a ‘‘naturalis-
tic’’ study design more representative of routine
clinical practice, AOM 400 was well tolerated
and had significantly greater effectiveness than
paliperidone LAI overall and in younger
patients aged B35 years.
Conclusion: Results across the ‘‘full spectrum’’
of efficacy in traditional clinical trials as well as
those encompassing the concept of effective-
ness in a more naturalistic setting of real-life
clinical practice support the use of AOM 400 as
a valid long-term treatment option in
schizophrenia overall, as well as earlier in the
treatment course, and not solely in situations of
poor adherence or when oral antipsychotics
have failed.
Keywords: Adherence; Hospitalization; LAI
antipsychotics; Relapse; Remission; Schizophre-
nia and related psychotic disorders; Second-
generation
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Schizophrenia is a pervasive and disabling psy-
chotic chronic condition with a major burden
on patients, their families, and society [1, 2].
During their lifetime, about 1% of the world
population will develop schizophrenia, typi-
cally preceded by prodromal symptoms of psy-
chosis leading to a first psychotic episode and
starting in young adulthood, although the dis-
tressing condition can occur at any age [2, 3].
Individuals with schizophrenia have a shorter
life expectancy than the general population,
with an increased risk of physical illness, espe-
cially cardiovascular disease, as well as higher
rates of suicide and accidental injury [2, 4–6].
The long-term course of schizophrenia is
marked by episodes of partial or full remission
broken by relapses, while social and occupa-
tional functioning, quality of life and ability to
live an independent life are constrained, and
there is an increased risk of substance abuse,
suicide and violent behavior, especially during
the period of relapse [2, 7].
While the prevention of relapse, accompa-
nied by delusions, which may potentially cause
harm to the patient and their societal contacts,
hallucinations, and disorganized speech and
behavior, is a major challenge in schizophrenia,
the disease is also characterized by poor adher-
ence to antipsychotic medication leading to a
need for multiple rehospitalizations and a sub-
stantial direct and indirect cost burden [2, 8–12].
In this narrative review, we examine pub-
lished clinical data from the development of
long-acting injectable (LAI) formulations of
antipsychotic drugs and review the evidence for
the comparative effectiveness of oral versus
long-acting antipsychotics in the management
of schizophrenia, with a focus on the sec-
ond-generation antipsychotic LAI aripiprazole.
Evidence from studies with naturalistic/prag-
matic as well as explanatory trial designs is
presented, supported by the clinical experience
of the authors.
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Treatment of Schizophrenia: Ensure
the Continuity of Therapy
The development and introduction of antipsy-
chotic drugs significantly improved treatment
outcomes and quality of life for patients with
schizophrenia, and there is general acceptance
of their valuable contribution at all stages of
schizophrenia [2, 13–17]. Although an in-depth
discussion of all therapeutic options for patients
with schizophrenia is beyond the scope of this
article, it is clear that all patients affected by
schizophrenia will require long-term treatment.
Long-term pharmacological therapy in the
stable or maintenance phase should be indi-
vidually tailored to the needs and preferences of
the patient and directed at ensuring symptom
remission and control of relapses; moreover, the
patient’s level of psychosocial functioning,
independence and quality of life is maintained
or improved by long-term therapy, while the
monitoring for adherence and adverse effects of
treatment is continued [4, 14, 18].
Antipsychotic pharmacological therapy should
be accompanied by psychoeducational and
psychosocial interventions customized to the
patient, including occupational therapy, com-
munity-based treatment, family interventions,
vocational rehabilitation and,whenappropriate,
counseling and psychotherapy, behavior
therapy, and cognitive behavioral therapy
(CBT) [2, 13–15, 17]. UK guidelines recommend
CBT as first-line therapy in at-risk adult popula-
tions [2].
Effective antipsychotic medications, in par-
ticular long-acting injectable (LAI) formula-
tions, facilitate and support the patient’s ability
to benefit from interventions designed to
encourage successful rehabilitation and re-entry
into society [14].
Assuring continuity of treatment is essential
to the prevention of relapse, a key focus in the
treatment of schizophrenia. Therefore, thera-
peutic interventions that enhance treatment
adherence, such as LAIs, are a clinical priority
within the treatment plan. Data from a sys-
tematic review and meta-analysis show a
weighted 1-year relapse rate of 77% in patients
with a first episode of schizophrenia who
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discontinue antipsychotic therapy, increasing
to over 90% at 2 years, compared with a mean
relapse risk of 3% in those continuously treated
with antipsychotics [19]. Similarly, patients
completely adherent to their antipsychotic
medication are at significantly reduced risk of
hospitalization or emergency room visits for a
mental health reason [20]. It is also becoming
clear that early intervention in patients with
psychosis has a beneficial effect on long-term
outcomes, while, conversely, delaying access to
effective mental health services may slow or
prevent complete recovery, increase the risk of
relapse and lead to poor long-term clinical and
social outcomes [21]. Continuity of treatment
from the early stages of the disease may, indeed,
significantly reduce the risk of recurrence and
improve patient outcomes [22].
Antipsychotic drugs with LAI formulations
were developed to reduce the problem of
non-adherence, which is estimated to be as high
as 40% or more [10, 14, 23]. LAI antipsychotics
have a number of advantages over oral
antipsychotics. LAIs are formulated to maintain
stable therapeutic blood levels during the per-
iod between injections (commonly every 2–
4 weeks, with the exception of a new formula-
tion of paliperidone palmitate administered
every 3 months), reduce the need to remind
patients to take their medication, lack an abrupt
decline in blood level of the antipsychotic agent
if an injection is missed, avoid bioavailability
issues that occur with oral preparations (gas-
trointestinal absorption problems and hepatic
first-pass metabolism), and reduce the risk of
accidental or deliberate overdose [2, 14]. Fur-
thermore, LAIs facilitate the regular contact
between patients and physician essential for
effective monitoring of the patient’s progress,
allow physicians to rule out non-adherence as a
cause of relapse, and, should a patient miss an
injection, there remains some time to act to
avert a crisis [24]. However, potential disad-
vantages include reduced flexibility of admin-
istration, a potentially extended period of
titration to optimal dose, and a longer duration
required to achieve steady state, relative to oral
administration [25].
Long-acting formulations of second-genera-
tion antipsychotic drugs, including risperidone,
olanzapine, paliperidone and aripiprazole, have
been developed [25]. They provide physicians
with the opportunity of rapidly achieving
steady state of the antipsychotic agent, together
with good flexibility in available dosages. For
example, aripiprazole is available in a long-act-
ing formulation for administration once-
monthly at dosage of 400 mg.
Determining the appropriate duration of
antipsychotic therapy to ensure long-term
continuity of the maintenance phase of
schizophrenia is the subject of some debate.
There is evidence that, compared with contin-
uing treatment, there is a higher risk of relapse
if treatment is discontinued in patients despite
their being stable on antipsychotics for up to
5 years after an acute episode [26]. Therefore,
treatment guidelines such as those of the
Canadian Psychiatric Association and the
World Federation of Societies of Biological Psy-
chiatry (WFSBP) recommend continuation of
antipsychotic drugs for the treatment of first-
episode psychosis for at least 2 years after first
remission, with a minimum of 5 years of relap-
se-free stability before considering slow with-
drawal of antipsychotic drugs over an extended
period (6–24 months) in patients with a history
of recurrences [27, 28]. However, as with
long-term therapy for any chronic disease,
careful consideration of treatment-related side
effects must be undertaken. First-generation, or
typical, antipsychotic agents are associated with
significant and potentially disabling and dis-
tressing side effects, including extrapyramidal
side effects (parkinsonism, dystonia, akathisia,
tardive dyskinesia), lethargy, sedation and
weight gain [2]. Newer atypical or second-gen-
eration antipsychotics were developed to be
more effective while reducing the likelihood of
disabling side effects. In particular, they have a
lower risk of acute extrapyramidal symptoms
and tardive dyskinesia, although they may be
associated with other side effects, such as
weight gain, hyperprolactinemia and metabolic
effects [2].
Although LAI antipsychotics have often been
chosen only when oral formulations had failed,
and many clinicians adopt the position that LAI
antipsychotic agents should not be used as
first-line therapy for schizophrenia, there is
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good evidence for their use as a first-choice
treatment, supported by recent guidelines and
studies [14, 29]. A recent large ‘real-world’
cohort study of the use of oral and LAI
antipsychotics after the first hospitalization of
patients for schizophrenia found that less
than half [45.7%, 95% confidence interval
(CI) 43.7–47.6%] adhered to their discharge
antipsychotic during the first 60 days after dis-
charge [29]. However, there was a significantly
lower risk of all-cause antipsychotic discontin-
uation with LAIs, and LAIs significantly reduced
the risk of rehospitalization, compared with oral
antipsychotics. During a mean follow-up of
2 years, the adjusted hazard ratio (HR) for
rehospitalization for LAIs was about a third that
associated with oral antipsychotics (HR 0.36,
95% CI 0.17–0.75, P = 0.007) [29], indicating
that LAIs were associated with substantially
better outcomes. Indeed, the Texas Medication
Algorithm Program, following expert panel
review of the clinical evidence for the treatment
of schizophrenia, recommends that physicians
should assess and consider the use of LAIs when
schizophrenic patients are inadequately adher-
ent at any stage [30, 31]. Furthermore, the
French Association for Biological Psychiatry and
Neuropsychopharmacology guidelines for the
use and management of antipsychotic depots in
clinical practice recommend LAI antipsychotics
be considered as first-line treatment in the
majority of patients who require long-term
therapy [32].
The concept of ‘effectiveness’, that is, a
comprehensive pragmatic approach that inte-
grates aspects of efficacy, safety and tolerability
from the perspective of both patient and clini-
cian, is essential to the satisfactory evaluation of
a long-term treatment [33, 34]. The comparative
effectiveness of oral versus long-acting antipsy-
chotics has been addressed in a number of
studies, reviewed recently by Alphs et al. [35],
with inconsistent findings, and by Suzuki, who
places comparisons between oral and long-
acting antipsychotics in a clinical context,
commenting that results from randomized
comparative trials rely heavily on study design
and population [36]. These inconsistent find-
ings may be influenced by methodological
considerations in clinical study design; that is,
naturalistic/pragmatic versus explanatory trial
designs. Explanatory clinical trials are designed
to measure the efficacy of a treatment in a rel-
atively homogeneous patient population under
highly controlled and well-defined conditions
of frequent, intensive, and standardized clinical
assessments that make adherence to treatment
more likely than in routine clinical practice
[35]. Such trials are unlikely to recruit patients
at added risk of non-adherence, e.g., patients
with first-episode psychosis or substance abuse
disorders, or those with a history of violence.
In contrast, pragmatic trials measure the
effectiveness of an intervention in a more
heterogeneous patient population better repre-
sentative of a more naturalistic clinical practice
setting. Indeed, two large meta-analyses of
randomized controlled trials, which concluded
that there is no advantage of LAIs over oral
antipsychotics in preventing relapse and hos-
pitalization [37, 38], were largely dependent on
highly explanatory trials, whereas meta-analy-
ses that have included trials with more prag-
matic trial designs have shown significant
advantages for LAI formulations over oral
antipsychotic in the naturalistic setting [39–41].
LAI formulations have been consistently supe-
rior to oral antipsychotics in mirror-image
studies which compare treatment periods with
oral antipsychotics with those of LAIs in the
same patients. Results from a recent systematic
review and meta-analysis of mirror-image stud-
ies showed strong superiority of LAIs compared
with oral antipsychotics in preventing hospi-
talization in patients with schizophrenia [42].
Despite evidence that LAI antipsychotics are
highly efficacious in schizophrenia, and some
real-world evidence suggesting that prescribed
LAI antipsychotics are often used concomi-
tantly with oral antipsychotics and psy-
chotropics [43], LAI antipsychotics remain an
underutilized treatment option.
In fact, there is research to show that
underutilization of LAIs originates more from
ideologic hesitation and attitudinal barriers on
the part of psychiatrists and physicians rather
than on any skepticism from patients towards
LAI drugs [44–48], and there is increasing
acceptance that psychiatrists should consider
the use of LAIs as a treatment option more often
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Aripiprazole is a second-generation antipsy-
chotic. Unlike other currently available first-
and second-generation antipsychotics, the
antipsychotic efficacy of aripiprazole has been
mainly attributed to a combination of partial
agonism at human dopamine D2 and serotonin
5-HT1A receptors and antagonism at serotonin
5-HT2A receptors [50–53]. Aripiprazole exhibits
high affinity for dopamine D2 and D3, sero-
tonin 5-HT1A and 5-HT2A receptors, moderate
affinity for dopamine D4, serotonin 5-HT2C and
5-HT7, a1-adrenergic and histamine H1 recep-
tors, and moderate affinity for the serotonin
reuptake site [54]. Consequently, aripiprazole
has a low potential for clinically relevant
weight gain, sedation, or metabolic adverse
events [54–58].
Aripiprazole is well absorbed and widely
distributed throughout the body [54]. Com-
pared with Cmax of the tablet formulation,
geometric mean maximum concentration is
higher (mean 19%) with aripiprazole 5 mg
short-acting intramuscular (IM) administra-
tion [59]. Systemic exposure is generally
similar after aripiprazole IM injection and
after oral tablet administration, over 24 h,
and the IM route of administration is not
expected to alter aripiprazole metabolic
pathways [59]. Aripiprazole dose is to be
reduced with concomitant administration of
potent CYP3A4 or CYP2D6 inhibitors and
should aripiprazole be given concomitantly
with potent CYP3A4 inducers, aripiprazole
dose is to be increased [54].
An extended release formulation of
aripiprazole [Abilify Maintena; aripiprazole
400 mg once-monthly (AOM 400)] has been
developed [60]. AOM 400 and 300 are both
approved in Europe for maintenance therapy of
schizophrenia in adult patients stabilized with
oral aripiprazole. The formulation is a powder
to be reconstituted in sterile water for IM
injection in the gluteal or deltoid muscle [60].
The pharmacokinetics, tolerability and safety of
aripiprazole once-monthly were investigated in
a 24-week, open-label, parallel arm pharma-
cokinetic study that established a recom-
mended dose of 400 mg [61], both as first and
maintenance dose. AOM 400 provided sus-
tained mean plasma concentrations of arip-
iprazole comparable to those achieved with
multiple consecutive daily doses of oral arip-
iprazole 10–30 mg/day at steady state, without
any clinically meaningful changes in adverse
events, laboratory values, vital signs, or elec-
trocardiogram measurements [61].
The recommended maintenance dose of
AOM, 400 mg, can be reduced to 300 mg in the
advent of adverse events or in patients who are
known to be cytochrome P450 (CYP) 2D6 poor
metabolizers. Patients taking AOM 400 con-
comitantly with strong CYP3A4 (e.g., ketocona-
zole, itraconazole) or strong CYP2D6 inhibitors
(e.g., fluoxetine, paroxetine, quinidine) formore
than 14 days also require a dose reduction to
300 mg [60]. Concomitant administration of
AOM in patients taking CYP3A4 inducers (e.g.,
carbamazepine, rifampicin, phenobarbital) for
more than 14 days is forbidden.
The registrational trials for AOM 400 con-
sisted of two pivotal international randomized,
double blind, multicenter, phase III studies
that compared AOM 400 either with placebo
[55] or with active and sub-therapeutic
threshold treatments [62] in adults aged 18–-
60 years meeting DSM-IV-TR schizophrenia
criteria and requiring maintenance antipsy-
chotic therapy. Time to impending relapse (the
primary endpoint) was significantly delayed
with AOM 400 relative to placebo [55], while
AOM 400 was non-inferior to oral aripiprazole
(10–30 mg) and superior to a subtherapeutic
dose (50 mg) of once-monthly aripiprazole, for
the primary endpoint of impending relapse
rate [62]. AOM 400 was shown to be well tol-
erated in both studies, with minimal injection
site pain and a safety profile consistent with
comparators and with that reported for oral
aripiprazole in previous registrational mainte-
nance studies [55, 62].
In the placebo-controlled study, as well as
significantly delaying time to impending
relapse compared with placebo, AOM 400
reduced relapse rates, with 39.6% of placebo
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recipients meeting criteria for relapse at the
52-week final analysis, compared with 10.0% of
AOM 400 recipients (HR 5.03, 95% CI
3.15–8.02) [55]. Mean positive and negative
syndrome scale (PANSS) total scores improved
from a mean of 65.1 during the oral aripiprazole
and AOM stabilization phases, and were similar
in both groups at the double blind baseline
(54.4 for placebo and 54.5 for AOM 400). In
patients randomized to AOM 400, the
improvements in PANSS total scores were
maintained throughout the 52-week treatment
period (mean change of ?1.4), while significant
increases in mean PANSS total scores were
observed in the placebo group from as early as
week 2 and continued at all time points (?11.6
at week 52, P\0.0001). As the efficacy of AOM
400 was demonstrated at the preplanned
interim analysis, the study was terminated early
to avoid further exposure to placebo.
In the active-controlled non-inferiority
study, PANSS total scores deteriorated in the
aripiprazole once-monthly 50-mg group during
the treatment phase, and there were statistically
significant differences for AOM 400 versus both
aripiprazole once-monthly 50 mg and oral
aripiprazole at week 38 (study end). At week 38,
the change from baseline in PANSS total score
was –1.66 for AOM 400, ?0.58 for oral arip-
iprazole, and ?3.08 for aripiprazole once-
monthly 50 mg (P = 0.0272 for AOM 400 vs.
oral aripiprazole and P = 0.0002 for AOM 400
vs. aripiprazole once-monthly 50 mg) [62].
In these and other key phase III studies, 90%
of patients across studies who were initiated on
the AOM 400 mg dose remained on that dose
throughout, and rates of discontinuation due to
lack of efficacy were in the order of 2%–10%
[55, 62–64]. As well as confirming 400 mg as an
effective, safe and well tolerated initial dose in
schizophrenic patients, Raoufinia et al.
demonstrated that the efficacy, safety and tol-
erability of AOM 400 in patients who were sta-
bilized with oral aripiprazole for 2 weeks after
the 1st injection of once-monthly aripiprazole
was consistent regardless of whether patients
were previously stabilized on oral aripiprazole
10 or 30 mg/day [64]. Overall, the pivotal
studies have shown that AOM 400 produces an
effective therapeutic effect over extended peri-
ods of up to 52 weeks.
In a naturalistic study in a community set-
ting, switching patients from oral antipsy-
chotics to AOM 400 significantly reduced
hospitalization rates (2.7% vs. 27.1% at
3 months and 8.8% vs. 38.1% at 6 months,
P\0.0001) [56]. This supports evidence from a
meta-analysis showing that LAIs are more
effective in reducing the rates of hospitalization
of patients with schizophrenia than oral
antipsychotics [65].
The QUAlity of LIfe with AbiliFY Maintena
(QUALIFY) study [57] is one of a very limited
number of randomized studies designed as a
head-to-head comparison of the effects of two
second-generation LAI antipsychotics with dif-
ferent mechanisms of action on health-related
quality of life and functioning. In this study,
AOM 400 was compared with paliperidone
palmitate once monthly. In contrast to more
traditional pivotal studies, the QUALIFY study
design integrated ‘‘pragmatic’’ or ‘‘naturalistic’’
features, more similar to real-life clinical practice
settings. Rather than assessing affectivity and
cognition as primary outcomes, the chosen pri-
mary endpoint was change in the Hein-
richs–Carpenter Quality-of-Life Scale (QLS), a
health-related quality-of-life scale that assesses
intrapsychic, social, and negative symptoms
and their consequences for functioning in
schizophrenia [60] This endpoint reflects a key
long-term aimof antipsychotic therapy. TheQLS
consists of 21 items in 4 domains consisting of
Interpersonal Relationships (8 items), Instru-
mental Role (4 items), Intraphysic Foundations
(7 items), and CommonObjects and Activities (2
items) [66]. Items are ratedona7-point scale for 0
(severe impairment) to 6 (normal/unimpaired
functioning) with a total score between 0 and
126; a higher score indicates better quality of life
and/or functioning. A difference of 5.3 points on
the QLS total score is considered to be clinically
meaningful [67]. The effects of treatment on
clinical symptoms were evaluated using the
CGI-S scale, which provides the physician’s
impression of the current state of mental illness
of the patient on a 7-point scale (from 1, normal/
not at all ill) to 7 (extremely ill) [57].
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QUALIFY was a 28-week, randomized,
non-inferiority, open-label, rater-blinded, head-
to-head study that comprised oral conversion to
IM injection of AOM 400 or paliperidone
palmitate treatment [flexible dosing, per label,
50–150 mg of paliperidone per month (EU and
Canada) or 78–234 mg of paliperidone palmi-
tate per month (US)] and continuation of IM
injections every 4 weeks. A total of 295 patients
were randomized to treatment, and 183 patients
(68% of the AOM group and 57% of the
paliperidone once-monthly group) completed
the study. The primary endpoint was designed
to determine non-inferiority and superiority
based on change in QLS total score from base-
line to week 28, utilizing a mixed model for
repeated measurements. The non-inferiority
criterion was met if the lower bound of the
two-sided 95% CI was greater than -5
(non-inferiority margin) for the least squares
mean (LSM) treatment difference in change in
QLS from baseline at week 28 for AOM 400
versus paliperidone palmitate. If met, a prede-
fined test of superiority was to be conducted.
Superiority of AOM 400 over paliperidone
palmitate was taken to be confirmed if the lower
bound of the two-sided 95% CI was[0 [57].
LSM change from baseline to 28 weeks in
QLS total score was 7.47 ± 1.53 for AOM 400,
relative to 2.80 ± 1.62 for paliperidone palmi-
tate; a statistically significant LSM difference
between treatments of 4.67 (95% CI 0.32–9.02,
P = 0.036) confirming the non-inferiority and
establishing superiority of AOM 400 over
paliperidone palmitate [57]. The variation in
QLS from baseline seen with AOM 400 repre-
sents a clinically relevant improvement in
health-related quality of life and functioning. In
pre-defined clinical and treatment effectiveness
analyses, AOM 400 was also consistently supe-
rior to paliperidone palmitate in younger
patients (B35 years). In this group, the LSM
treatment difference from baseline at week 28
favoring AOM 400 was 10.7 (95% CI 0.70–20.7,
P = 0.037); results which appear to indicate a
greater treatment benefit with aripiprazole in
younger patients than that seen with paliperi-
done [57].
Adverse events were the most common rea-
son for patient discontinuation in the study
(AOM 400: 11.1%; paliperidone palmitate:
19.7%). Treatment-emergent adverse events
(TEAEs) were more frequent with paliperidone
palmitate rather than AOM 400. The most fre-
quent TEAEs during the 20-week LAI continua-
tion phase of the study were weight gain,
psychotic disorder, and insomnia, all of which
occurred more frequently in paliperidone
palmitate-treated patients. Extrapyramidal symp-
toms were uncommon and occurred in less than
5% of patients in each group.
There were also significant improvements in
secondary endpoints, including CGI-S scale.
Clinical symptoms were significantly more
improved at week 28 with AOM 400 compared
with paliperidone palmitate (LMS between-
treatment difference in change from baseline
-0.28, 95% CI -0.48 to -0.09, P = 0.004) when
assessed with the CGI-S score. This effect was
even more pronounced in younger patients
(B35 years) in whom the LMS between-treat-
ment difference in change from baseline in
CGI-S was -0.44 (95% CI -0.83 to -0.06,
P = 0.026) in favor of AOM 400.
Post hoc analyses of data from the QUALIFY
study have shown that the superior improve-
ments in health-related quality of life and
functioning were accompanied by a reduced
risk of sexual dysfunction and lower elevation
of prolactin levels with AOM 400, compared
with paliperidone palmitate [68]. These effects
may be related to the differential activity of
aripiprazole and paliperidone on the dopamine
D2 receptor.
Expert Opinion
The prevention of relapse, improving the qual-
ity of life and psychosocial functioning of the
patient and maintaining recovery are key
long-term goals of pharmacological therapy for
schizophrenia. Relapse can be distressing for the
patient and their caregivers and threatens the
patient’s ability to live an independent life,
increasing the burden of care and the risk of
rehospitalization and relative costs. In addition,
when relapse is impending or present, rates of
substance abuse, suicide and violent behavior
rise [2, 7]. Assuring continuity of treatment is
key for the prevention of relapse, as almost all
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patients with schizophrenia will relapse if
antipsychotic therapy is discontinued [19, 26].
Due to its pharmacological profile, aripipra-
zole represents an innovative therapeutic
choice for major psychiatric disorders. Its
modulatory properties on different neurotrans-
mitter systems highlight a drug with a broad
pharmacological profile and clinical effective-
ness in the acute and long-term treatment, as
demonstrated in different clinical trials [69].
The LAI formulation of aripiprazole at dose
of 400 mg (AOM 400) is effective in reducing
the risk of relapse, and it is well tolerated with a
safety profile comparable to oral aripiprazole
[55, 62]. Because of its specific mechanism of
action and as demonstrated in clinical studies,
AOM 400 has important effects on both positive
and negative symptoms of schizophrenia, so
that it provides a valid treatment option for
patients with a prevalence or persistence of
negative symptoms (with or without cognitive
dysfunction), also induced by other antipsy-
chotics (e.g., haloperidol, risperidone and
paliperidone) such as decreased ability to initi-
ate tasks, affective blunting, apathy, abulia,
lowered levels of motivation or drive and poor
social relationships. Based on the clinical expe-
rience of the authors, after AOM 400 introduc-
tion, an improvement of positive and negative
symptoms accompanied by a decrease in epi-
sodes of irritability was reported, which allowed
the patients to increase social (e.g., interaction
with family, active social life, establishment of
socio-sexual relationships) and working (e.g.,
return to work, ready for work, satisfaction with
the work) functioning and ameliorate the
overall quality of life. All these factors further
enhance adherence to treatment.
Of particular importance is the QUALIFY
study, which had a more naturalistic study
design than traditional pivotal studies, and
which used the QLS scale as a primary endpoint
to compare the effectiveness of AOM 400 and
paliperidone palmitate [57]. As a widely used
and validated health-related quality of life
measure which focuses on intrapsychic, social
and negative symptoms, the QLS is valuable
in measuring functioning in schizophrenia,
including response to pharmacological therapy
[66]. The four domains of QLS, i.e. intrapsychic
foundations (e.g., sense of purpose, motivation,
curiosity, anhedonia, aimless inactivity, empa-
thy, emotional interaction), interpersonal
relationships (e.g., household, friends, acqu-
aintances, social activity and network and ini-
tiative, withdrawal, sociosexual), instrumental
role (e.g., occupational role, work functioning,
work level, and work satisfaction), and com-
monplace objects and activities (participation
in the community) reflect all of the aspects that
the clinician evaluates regarding quality of life
in the clinical practice and represent a central
long-term goal of antipsychotic therapy for
clinicians and patients.
In QUALIFY, as well as producing a statisti-
cally significant difference in QLS total score
relative to paliperidone palmitate, AOM 400
significantly improved the intrapsychic foun-
dations domain of the QLS, which also includes
negative symptoms, contributing most to the
greater, and clinically relevant, improvement in
patient functioning seen with AOM 400, com-
pared with paliperidone palmitate [57]. Based
on the clinical experience of the authors, the
important positive effect of aripiprazole LAI on
clinical symptoms, functioning and health-re-
lated quality of life is pivotal in order to involve
patients in rehabilitation programs, obtaining
long-term continuity.
Furthermore, AOM 400 was particularly effec-
tive in younger patients, with a between-treat-
ment difference of 10.7 points in patients aged
B35 years,which is larger than thenon-inferiority
margin of minus 5 points and approximately
double the 5.3-point difference from baseline
estimated by Falissard et al. to be the minimal
clinically important difference for QLS [67].
Another key secondary endpoint, CGI-S, which
showed significant improvements from baseline
at study end with AOM 400 relative to paliperi-
done palmitate, was also greater in younger
patients [57].
This evidence supports the benefits of early
intervention with LAIs, seen in other studies
[14, 21, 70], with early intervention in patients
with schizophrenia improving clinical and psy-
chosocial long-termoutcomeswhile, on theother
hand, the risk of relapse or poor long-term out-
comes increases when access to effective mental
health services is delayed. Newly diagnosed
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patients may not be fully aware of or have fully
accepted the seriousness of their illness, and they
are often less adherent, making the use of a
long-acting medication a sensible strategy to be
considered [24]. Treatment considerations that
tend to reserve LAIs for patients in stages of the
disease when the symptoms are most severe,
when treatment with oral medications fails, or
when there are problems of poor adherence
should be reexamined. Daily interactions
between caregivers and the patient to ensure
compliance with oral antipsychotic medications
can be negative and stressful. With its demon-
strated efficacy and effectiveness and uncertainty
about adherence removed, AOM 400 may be of
particular benefit for younger patients.
Despite the apparent reluctance of some
physicians to offer LAIs, even when the poten-
tial benefit to the patient is clear, in the clinical
experience of the authors switching to AOM
400 from other LAIs or oral antipsychotics was
completely manageable. A discussion of opti-
mal switching strategies to AOM from other
antipsychotic agents is beyond the scope of this
article. However, strategies for switching have
been discussed by recent expert consensus
panels [71, 72], and a recent article by Raoufinia
et al. [64] provides a rationale and details rec-
ommended strategies for the initiation of AOM
in patients with schizophrenia. The effects of
AOM 400 are apparent from the start of therapy,
and rapid amelioration of symptoms was
noticed by caregivers and contributed to patient
satisfaction with treatment. A recent study that
evaluated hospitalization rates in patients swit-
ched from oral antipsychotics to AOM 400 [56]
found that the number of psychiatric hospital-
izations significantly reduced after switching to
AOM, further supporting the effectiveness of
using AOM in the community setting.
The safety and tolerability of AOM 400
was comparable to previous experience with
orally-administered aripiprazole, with minimal
weight gain or changes in metabolic parameters
and prolactin levels [56]. Administration of AOM
400 is straightforward, with minimal injection
site pain and a reduced need for concomitant
treatment with other antipsychotic compounds
to achieve treatment aims. Patient-reported
treatment satisfaction with AOM is high after
switching to AOM 400 maintenance therapy,
with patients describing positive perceptions of
tolerability with no or fewer side effects with
AOM 400 than with prior antipsychotic medi-
cation [73]. The authors have, in their clinical
practice, patients on AOM 400 therapy for over
30 months that have maintained a good quality
of life without relapses or rehospitalization.
Patient satisfaction with therapy allows patients
to return to a productive life with enhanced
social relationships and work reintegration. The
effective control of symptoms, reduced rates of
sexual dysfunction, hyperprolactinemia, meta-
bolic effects, and extrapyramidal symptomswith
AOM 400 make it particularly suited for patients
with these side effects from other antipsychotic
medications.
Taking into account all of the considera-
tions above, the choice of using AOM 400 in
clinical practice might be oriented on young
patients, who can hence benefit more from a
long-acting treatment effective on clinical
symptoms, functioning and quality of life, on
patients presenting a history of positive and
negative symptoms with or without cognitive
impairments, and on patients experiencing
persistent side effects with the current treat-
ment such as metabolic effects, weight gain,
extra-pyramidal symptoms and sexual prob-
lems. Nevertheless, the promising results
across the ‘‘full spectrum’’ of efficacy in tra-
ditional clinical trials, as well as those
encompassing the concept of effectiveness in
a more naturalistic setting of real-life clinical
practice, support the use of AOM 400 beyond
situations of poor adherence or when oral
antipsychotics have failed. Although further
studies are required to fully define the role of
AOM 400 in the treatment of schizophrenia,
evidence is now available for its use across
the continuum of patients encountered in
clinical practice.
CONCLUSIONS
Long-acting injectable antipsychotics can play
an important role in enhancing adherence,
preventing relapse, and reducing hospitaliza-
tions in patients with schizophrenia. Evidence
Adv Ther
from traditional ‘‘explanatory’’ clinical trials
under highly controlled and well-defined con-
ditions, together with that from more ‘‘natu-
ralistic’’ or ‘‘pragmatic’’ studies encompassing
the concept of effectiveness in a naturalistic
setting more representative of real-life clinical
practice, support its early use and suggest a
broader role for AOM as a valid long-term
treatment option in the treatment of
schizophrenia, not just in situations of poor
adherence or when oral antipsychotics have
failed.
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